Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
131I-MIBG Combinations in Relapsed or Refractory Neuroblastoma
NCT07261241Phase 2Not yet recruiting
- Sponsor
- New Advances in Neuroblastoma Therapy
- Start
- Dec 2026
- Primary completion
- Dec 2030
- Modality
- Monoclonal Antibodies, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Iobenguane I-131, vorinostat, dinutuximab in neuroblastoma, sponsored by New Advances in Neuroblastoma Therapy. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
Iobenguane I-131vorinostatdinutuximab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT07261241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07261241.